Discussion
CINV
INJECTION SITE REACTION
To the best of our knowledge, this is the first study to provide efficacy and safety data on a multiple-day course of fosaprepitant combined with a 5-HTFor acute nausea and vomiting symptoms seen after chemotherapy, no difference in incidence was found between the two treatment groups. Consistent with previous research results, the acute phase is mainly mediated by 5-HTOur findings demonstrate the efficacy of multiple-day fosaprepitant in preventing CINV, particularly in the delayed phase, which has a significant negative impact on a patient’s daily life [It is worth noting that antiemetic trials typically evaluated CINV control for 120 h (in the acute phase and delayed phase). An observation study, on the other hand, reported the presence of a certain number of patients who developed CINV after 120 h, implying the importance of monitoring for beyond delayed CINV that develops after 120 h [In our study, the regimen of adding an extra day of fosaprepitant was generally well tolerated, and no new safety signals were found when compared to previous fosaprepitant studies [It is worth noting that fosaprepitant has been reported to be associated with a high frequency of injection site reactions (ISRs), leading to clinical problems [Our new antiemetic combination targeting two critical antiemetic pathways, was safe, well tolerated and highly effective of HEC. It should be noted that the categories of emetics is only based on the incidence of acute CINV, not delayed or overall CINV [In conclusion, among patients receiving HEC regimen, prolonged use of fosaprepitant is effective and safe in preventing delayed CINV.